Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Retatrutide vs Survodutide: Two Glucagon-Arm Agonists, One With GIP

Retatrutide and survodutide both carry a glucagon arm . Survodutide (BI 456906, Boehringer Ingelheim and Zealand Pharma) pairs GLP-1 with glucagon; retatrutide adds GIP as a third arm. Separately reported results: retatrutide 24.2% at 48 weeks (Phase 2) and 28.3% at 80 weeks (TRIUMPH-1, sponsor-reported); survodutide up to 16.6% at 76 weeks (SYNCHRONIZE-1, efficacy estimand). Survodutide’s distinguishing programme is liver disease. Neither is approved, no head-to-head results exist, and New-U does not sell survodutide.

No head-to-head results exist. Doses, populations and endpoints differ, and survodutide’s programme is built around liver outcomes as much as weight, so a weight figure alone says nothing about its liver endpoints. Research context; nothing here is medical or dosing guidance. Regulatory and trial status is as of September 2026.

At a glance

Retatrutide Survodutide Receptor targets GIP + GLP-1 + glucagon (triple) GLP-1 + glucagon (dual) Developer Eli Lilly (LY3437943) Boehringer Ingelheim / Zealand Pharma (BI 456906) Cadence Once-weekly (trials) Once-weekly Headline weight data 24.2% at 48 wk (Phase 2); 28.3% at 80 wk (TRIUMPH-1, 12 mg) Up to 16.6% at 76 wk (SYNCHRONIZE-1, efficacy estimand) Distinguishing programme Obesity, type 2 diabetes and other conditions under study Obesity and MASH (FDA Breakthrough Therapy designation) Status Phase 3 (TRIUMPH); no approval Phase 3; no approval Research access GLP1-RC-RT (retatrutide reference) Not sold: proprietary

What the glucagon arm does

On its own, glucagon raises blood glucose. Paired with GLP-1 the glucose effect is intended to be offset, leaving the arms researchers care about: higher energy expenditure and mobilisation of fat from the liver. Both drugs rely on this logic. The difference is the third receptor. Retatrutide layers GIP on top, adding the incretin effects tirzepatide is known for; survodutide stays a focused GLP-1 and glucagon pairing aimed squarely at weight and liver.

Comparing the two is close to a controlled question about what a GIP arm adds to a GLP-1/glucagon design. That is exactly why the cross-trial numbers cannot answer it: the trials differ in more than the receptor list.

What the trials showed

Retatrutide (Phase 2, NEJM 2023, n=338): 17.1% (4 mg), 22.8% (8 mg) and 24.2% (12 mg) at 48 weeks against 2.1% on placebo. In TRIUMPH-1, Lilly reported 28.3% at 80 weeks on 12 mg.

Survodutide (SYNCHRONIZE-1, Phase 3, 76 weeks, adults with obesity or overweight without diabetes): both primary endpoints met, with up to 16.6% mean weight reduction on the efficacy estimand against 3.2% on placebo, as reported by Boehringer Ingelheim.

The dose ladders, analysis populations and durations differ, so the two sets of figures describe two programmes, not the molecules.

The liver angle

Because glucagon-receptor agonism has been associated with reduced liver fat in trials, survodutide is developed for MASH (metabolic dysfunction-associated steatohepatitis, the fibrosing form of fatty liver disease) as well as obesity, and it holds an FDA Breakthrough Therapy designation for non-cirrhotic MASH with moderate-to-advanced fibrosis. A designation is intended to expedite development and review; it is not an approval. Retatrutide’s published trials also report hepatic measures, but the two programmes are organised differently, and the liver evidence for each should be read from its own primary publications.

Research access

Survodutide is a proprietary Boehringer Ingelheim / Zealand Pharma molecule and New-U does not sell it. The survodutide research guide covers the MASH programme.

Research takeaway

Both drugs use a glucagon arm; retatrutide adds GIP, survodutide does not.

Separately reported weight figures are not comparable across the two programmes.

Survodutide’s programme centres on MASH as well as weight.

Neither is approved, no head-to-head results exist, and the other compound is proprietary and not sold by New-U.

Primary sources

New England Journal of Medicine — Triple–Hormone-Receptor Agonist Retatrutide for Obesity (Jastreboff et al., 2023)

Eli Lilly — TRIUMPH-1 topline results

Boehringer Ingelheim — Results from the Phase III SYNCHRONIZE-1 obesity trial

Retatrutide as a research reference (GLP1-RC-RT)

New-U catalogues laboratory research material under GLP1-RC-RT (retatrutide reference). Survodutide is a proprietary Boehringer Ingelheim / Zealand Pharma molecule and is not sold. The trial results above describe the sponsors’ investigational products, not this material. Published Certificates of Analysis are available for the batches listed in the COA library. Research use only – all claims made on this site are for testing and research use only.

Frequently asked questions

Is survodutide better than retatrutide?

No trial has compared them. Separately, survodutide reported up to 16.6% at 76 weeks (SYNCHRONIZE-1) and retatrutide 24.2% at 48 weeks (Phase 2) and 28.3% at 80 weeks (TRIUMPH-1, sponsor-reported). Programmes and endpoints differ. Research context only.

What is the difference between retatrutide and survodutide?

Survodutide is a GLP-1 + glucagon dual agonist. Retatrutide adds GIP-receptor agonism as a third arm. Survodutide’s programme also emphasises MASH.

Is survodutide approved?

As of September 2026, no. The sources reviewed report no marketing authorisation. Its FDA Breakthrough Therapy designation for MASH is intended to expedite development and review but is not an approval.

How does the glucagon arm relate to glucose in the trials?

Glucagon-receptor agonism alone raises glucose. In both programmes it is paired with GLP-1 agonism, and each programme’s trials report glycaemic and liver measures; read those from the primary publications.

Can survodutide be bought as a research compound?

No. It is proprietary and New-U does not sell it.

External links are provided for research reference only; New-U is not affiliated with the cited organisations. All figures are published trial results shown for research context, not dosing guidance. New-U Research Compounds supplies research compounds strictly for laboratory research use only — not for human consumption .

Research-grade · >99% HPLC purity · COA per lot

Buy Retatrutide from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. Research use only - all claims made on this site are for testing and research use only.

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research